← FDA DRUG APPROVALS

FDA NDA · NDA213260

ATORVALIQ

Sponsor: CMP DEV LLC

APPLICATION
NDA213260
TYPE
NDA
ORIGINAL APPROVAL
2023-02-01
LATEST ACTION
2024-04-23
ROUTE
ORAL
DOSAGE FORM
SUSPENSION
MARKETING STATUS
Prescription

Products

ATORVALIQ · ReferencePrescription
ATORVASTATIN CALCIUM 20MG/5ML · SUSPENSION · ORAL

Approval history

2024-04-23Labeling · Supplement 2 · standard — Label ↗AP
2023-02-01Type 3 - New Dosage Form · Original · standard — Label ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →